FOSFOMYCIN TROMETHAMINE

Post-LOE

fosfomycin tromethamine

Aurobindo Pharma

ANDAORALFOR SOLUTION

Approved

Oct 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

FOSFOMYCIN TROMETHAMINE (fosfomycin tromethamine) by Aurobindo Pharma is clinical pharmacology absorption: fosfomycin tromethamine is rapidly absorbed following oral administration and converted to the free acid, fosfomycin. Approved for pyelonephritis, perinephric abscess. First approved in 2021.

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Absorption: Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to the free acid, fosfomycin. Absolute oral bioavailability under fasting conditions is 37%. After a single 3-gram dose of fosfomycin tromethamine, the mean (± 1 SD) maximum…

Worked on FOSFOMYCIN TROMETHAMINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

FOSFOMYCIN TROMETHAMINE

Mechanism of Action

Indications (2)

Clinical Trials (1)